On Tuesday, Shares of Anthem Inc (NYSE:ANTM), gained 1.87% to $146.53. 2.29 million shares of the company were exchanged.
Anthem, Inc. (ANTM) declared that Jose Tomas, executive vice president and chief human resources officer of the company, has become a National Association of Corporate Directors (NACD) Fellow, the highest level of credentialing for corporate directors and corporate governance professionals. Tomas presently serves as a board member and governance committee chair for the Society for Human Resource Administration (SHRM) and holds a Senior Certified Professional (SHRM-SCP) certification.
As an NACD Fellow, Tomas has demonstrated his knowledge of the leading trends and practices that define exemplary corporate governance recently and has committed to developing professional insights through a sophisticated course of ongoing study.
Candidates for NACD’s Fellowship Program complete a strong foundation course which focuses on topical matters and committee-specific issues, followed by additional NACD education within a 12-month period. NACD Fellows renew their status every year, maintaining and advancing their knowledge with continuous learning and peer-led collaboration.
Anthem, Inc., through its auxiliaries, operates as a health benefits company in the United States. It operates through three segments: Commercial and Specialty Business, Government Business, and Other.
Shares of NXP Semiconductors NV (NASDAQ:NXPI), declined -2.24% to $87.02, during its last trading session.
NXP Semiconductors N.V. (NXPI) declared it will release financial results for the third quarter of 2015 after the close of extended trading on the NASDAQ Global Select Market on Wednesday, October 28, 2015. The release will be followed by a conference call with the financial community on Thursday, October 29, 2015 at 8:00 AM U.S. Eastern Daylight Time.
NXP also declared recently that the regulatory approval process on the NXP-Freescale Semiconductor (“FSL”) merger and the sale of NXP’s RF Power business is progressing as anticipated. NXP believes it is on track to close the transactions, counting the sale of the RF Power business to Beijing Jianguang Asset Administration Co., Ltd. (JAC Capital), in the fourth quarter of 2015. Next to the already received clearances, counting the clearance received from the European Commission, NXP anticipates clearance decisions in the USA, China and South Korea. In the meantime, the Committee on Foreign Investment in the United States (CFIUS) has accomplished its action on the NXP-FSL merger. CFIUS has informed NXP and JAC Capital that it will conduct a 45-day investigation of the sale of the RF Power business that is predictable to be accomplished no later than November 23, 2015.
NXP Semiconductors N.V., a semiconductor company, provides high performance mixed signal and standard product solutions for radio frequency (RF), analog, power administration, interface,
At the end of Tuesday’s trade, Shares of Mallinckrodt PLC (NYSE:MNK), declined -1.34% to $65.01.
Mallinckrodt plc (MNK), a leading specialty biopharmaceutical company, declared that data from a pilot study for its H.P. Acthar Gel (repository corticotropin injection) will be presented at the American College of Rheumatology (ACR) 2015 Annual Meeting to be held November 7-11 in San Francisco.
The company-sponsored pilot study, titled “Repository Corticotropin Injection (H.P. Acthar Gel) Attenuates Disease Activity in Patients with Persistently Active Systemic Lupus Erythematosus (SLE) Requiring Corticosteroids,” was an eight-week, double-blind, randomized, placebo-controlled study that assessed clinical efficacy of repository corticotropin injection in patients with persistently active SLE despite moderate dose corticosteroids. An open label extension of this study is ongoing. Acthar is approved by the U.S. Food and Drug Administration for use during an exacerbation or as a maintenance therapy in select patients with SLE.
The poster will be presented at the ACR Annual Meeting at 9:00 a.m. Pacific Time on Sunday, November 8, by the lead investigator, Richard A. Furie, M.D. Dr. Furie is Chief of the Division of Rheumatology, Hofstra North Shore LIJ School of Medicine, Great Neck, New York. The abstract is presently accessible on the ACR website.
Mallinckrodt Public Limited Company develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents worldwide. The company operates through two segments, Specialty Pharmaceuticals and Global Medical Imaging.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties, which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified with such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should/might occur.
